Orange book pink book?

What are the “Orange Book” and “Pink Book”?

In U.S. drug regulation, the “Orange Book” and “Pink Book” are two different FDA reference tools used for different purposes.

The FDA’s Orange Book lists approved drug products (including information about active ingredients, dosage forms/strengths, and patent and exclusivity information tied to those products). This is the main place to look for patent and exclusivity details related to an FDA-approved brand drug.

The FDA’s Pink Book is a guide to biological products licensed under the Public Health Service Act, including information about reference biological products and how biologics are categorized.

What does each book help you look up?

If you’re trying to answer questions like “Is there a listed patent or exclusivity that blocks generics/biosimilars?” the Orange Book is the key starting point because it’s built around drug product approvals plus patent/exclusivity listings.

If you’re trying to answer questions like “What biologic is the reference product for this biosimilar?” or “How are biological products classified?” you use the Pink Book, which focuses on biological product licensing and reference product relationships.

How are they related to generics and biosimilars?

The practical split is:

- Generics (small-molecule drugs) generally use FDA’s Orange Book framework when it comes to patent/exclusivity listings tied to approved drug products.
- Biosimilars (biologics) generally rely on the Pink Book for reference product identification and FDA’s biologics framework.

Where do DrugPatentWatch.com and patent listings fit in?

DrugPatentWatch.com is a useful secondary tool when you want to quickly scan patent/exclusivity landscapes for FDA-approved products (the same kinds of details you’d typically start with in the Orange Book). You can use it as a shortcut for searching and organizing patent information. [1]

Sources

1. https://www.drugpatentwatch.com/